Postpartum depression is common, with estimates ranging from about one in eight to one in five new mothers depending on how it is defined and measured, and current treatments leave a substantial share of them symptomatic, ambivalent, or disengaged. Against that backdrop, a theoretical framework called MINDS, Matrescent Integration via Neuroplasticity, Dyads, and Psilocybin, makes a specific argument: that psilocybin research has already cleared the evidentiary bar needed to study postpartum women directly, and that the field’s continued caution reflects institutional inertia as much as scientific uncertainty. This desk asked a Johns Hopkins researcher who studies psychedelic adverse events for a living to respond to that claim directly. Her answer does not dismiss the underlying urgency. It names four specific things the field’s most advanced postpartum psychedelic drug candidate has not yet done, and argues those gaps, not general caution, are what stands between where the evidence sits today and where MINDS says it already is.

What MINDS argues

MINDS is a theoretical, literature-based framework developed by researcher Amanda Wilde, built around a specific claim: that existing postpartum depression research and drug development treat the individual mother as the unit of analysis, when the mother-infant dyad, and the broader developmental process of matrescence, becoming a mother, is the more accurate frame for both the condition and its treatment. Wilde’s own account of the evidence base draws on more than randomized trials. She points to the roughly 411-participant Mothers of the Mushroom self-report survey, indigenous ceremonial use in Oaxaca, and personal accounts from mothers she knows directly, arguing that if anecdotal and traditional-use evidence counts as evidence at all, “we have met a reasonable evidence threshold for roughly the last five to eight years.” On safeguards, Wilde describes an explicit expectation that dosing-day caregiving falls to a trusted adult, not the mother, and structured follow-up at defined intervals after dosing. She has also disclosed a real, direct stake in the framework’s future: plans for intellectual property protection, speaking engagements, and eventual hospital pilot programs, training, and certification built around MINDS.

Where the drug-development track stands

The most advanced psychedelic-adjacent drug specifically targeting postpartum depression is luvesilocin, developed by Reunion Neuroscience under the name RE104 before its current designation. The compound’s Phase 1 safety trial, conducted in 2024, enrolled 48 healthy volunteers, roughly 75 percent of them male. The company moved directly from that trial into RECONNECT, a Phase 2 study dosing postpartum patients, which reported about 71 percent remission at Day 7 in its 30 milligram arm, against 41 percent in a low-dose active-comparator arm rather than an inert placebo, and earned FDA Breakthrough Therapy designation in February 2026. That sequence, a small, predominantly male safety population followed directly by dosing in postpartum women, is the specific structural fact against which any claim about the field’s current evidence base has to be measured.

What outside scrutiny of the drug evidence finds

This desk asked Ceyda Sayali, a cognitive neuroscientist and psychopharmacologist at Johns Hopkins’s Center for Psychedelic and Consciousness Research whose published work includes direct characterization of adverse events in psilocybin trials, to respond to MINDS’s evidentiary claim on its merits. Her answer was specific rather than categorical. Asked what rigorous safety evidence would need to look like before a serotonin 2A receptor-active compound moves toward broader postpartum use, she said plainly: “safety data generated in the population itself, over a longer timeline, covering both mother and infant, before the current trajectory toward Phase 3 and broader use.”

Asked whether reproductive state itself could plausibly change how the brain responds to a psychedelic, independent of any single compound or study, her answer supplied a mechanism rather than speculation alone. She pointed to work from the same UC Davis lab, Hatzipantelis and Stolzenberg, whose mouse study on postpartum psilocybin exposure this desk examined directly in an earlier piece: that team’s own follow-up research found that childbirth triggers a hormone-driven, region-specific reorganization of serotonin receptors in the brain. “Postpartum hormonal changes reorganize serotonin signaling unevenly across brain regions, so a 5-HT2A agonist could engage circuits differently than it would in a non-postpartum brain, activating regions meant to be quiet, or missing ones upregulated for maternal care.” She was careful to frame this as the study authors’ own speculation rather than established fact, and to note that the mechanism, if real, would apply to any 5-HT2A-active compound generally, not to psilocybin or luvesilocin specifically.

Her sharpest answer addressed the methodological gap directly, and it names exactly the comparison this desk has been building toward across its own coverage of this drug class. The 2025 Nature Communications mouse study found psilocybin helped non-postpartum mice while harming postpartum mice weeks after dosing, and caused anhedonia in nursed offspring, a delayed-onset effect. Reunion’s human trial program, by contrast, moved from a small, mostly male Phase 1 directly into postpartum dosing, with primary assessment windows at day seven and week four, a timeline that ends before the mouse study’s harm signal even emerged. What Sayali names as absent: dose-response and receptor-engagement data generated specifically in postpartum subjects, human follow-up extending meaningfully past those early checkpoints, infant outcome tracking through lactational exposure directly rather than milk-concentration measurement alone, and a trial comparing the drug against an existing postpartum depression medication rather than placebo alone.

Two claims that are not in conflict

MINDS’s central argument and Sayali’s response are not answering the same question, and treating them as opposing positions on identical ground would misrepresent both. MINDS argues that the threshold for beginning postpartum-specific research, given the scale of unmet need and the existence of anecdotal and traditional-use evidence, has already been met. Sayali’s answer addresses a narrower and more specific question: what evidence would need to exist before a specific compound now moving toward Phase 3 and broader clinical use could be considered adequately characterized for safety in this population. It is entirely possible to agree that postpartum-specific research is overdue while also concluding, as Sayali’s answer does, that the specific evidence package behind the field’s leading drug candidate has real, nameable gaps. MINDS’s own account of what future studies should require, dosing-day separation from infant caregiving, structured follow-up intervals, is not inconsistent with Sayali’s list. It is less specific about the same underlying concerns.

The disclosures this desk is tracking

Wilde disclosed plans to eventually commercialize MINDS through intellectual property protection, training, certification, and hospital pilot programs. The thesis-review record is narrower than Wilde initially described. Daniel Roe, one of two thesis advisors, said he reviewed the full thesis for logical flow, basic copy editing, and general biological and psychological support, but not for ethics or safety. Ceyda Sayali separately confirmed that she served as Wilde’s thesis advisor and was comfortable being listed; she also said the relevant thesis section included safety, ethics, postpartum, and lactation-related limitations, though safety and lactation were mostly framed as missing evidence rather than developed as distinct limitation domains. Sayali’s responses to this desk’s questions were solicited and answered as a researcher speaking from her own published expertise, not in her advisory capacity, and this desk asked her the same category of question it has posed to researchers with no connection to Wilde’s work at all.

What remains open

This desk has also sought comment from Danielle Stolzenberg, the UC Davis researcher whose mouse study anchors much of this discussion, who has agreed to respond and whose answers were not yet available at the time of this piece’s publication, and from Kaytlin Krutsch, a lactation pharmacology researcher at the InfantRisk Center. If and when additional responses arrive, this desk will update this piece to include them, attributed and disclosed to the same standard applied here.

The frame

The honest state of the evidence, as this desk currently understands it, sits between the two positions this piece has laid out rather than fully inside either one. A real, serious unmet need exists, and MINDS is a considered attempt to organize research and clinical practice around that need using a framework, matrescence and the maternal-infant dyad, that current drug development largely ignores. It is also true, independent of what anyone thinks of MINDS specifically, that the field’s most advanced postpartum-specific psychedelic candidate has not yet generated the dose-response, extended follow-up, infant-outcome, or active-comparator data a researcher in this exact field says the population deserves before broader use. Both of those things can be true at once, and readers evaluating either the framework or the drug candidate it is responding to should hold both in view rather than resolving the tension in either direction prematurely.